132 related articles for article (PubMed ID: 27468779)
1. Sticky Patches on Lipid Nanoparticles Enable the Selective Targeting and Killing of Untargetable Cancer Cells.
Sempkowski M; Zhu C; Menzenski MZ; Kevrekidis IG; Bruchertseifer F; Morgenstern A; Sofou S
Langmuir; 2016 Aug; 32(33):8329-38. PubMed ID: 27468779
[TBL] [Abstract][Full Text] [Related]
2. Masking and triggered unmasking of targeting ligands on liposomal chemotherapy selectively suppress tumor growth in vivo.
Bandekar A; Zhu C; Gomez A; Menzenski MZ; Sempkowski M; Sofou S
Mol Pharm; 2013 Jan; 10(1):152-60. PubMed ID: 23134440
[TBL] [Abstract][Full Text] [Related]
3. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
4. Quantitative Study of the Interaction of Multivalent Ligand-Modified Nanoparticles with Breast Cancer Cells with Tunable Receptor Density.
Wang J; Min J; Eghtesadi SA; Kane RS; Chilkoti A
ACS Nano; 2020 Jan; 14(1):372-383. PubMed ID: 31899613
[TBL] [Abstract][Full Text] [Related]
5. The pH-dependent association with cancer cells of tunable functionalized lipid vesicles with encapsulated doxorubicin for high cell-kill selectivity.
Karve S; Bandekar A; Ali MR; Sofou S
Biomaterials; 2010 May; 31(15):4409-16. PubMed ID: 20189243
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, characterization, and biological verification of anti-HER2 indocyanine green-doxorubicin-loaded polyethyleneimine-coated perfluorocarbon double nanoemulsions for targeted photochemotherapy of breast cancer cells.
Lee YH; Ma YT
J Nanobiotechnology; 2017 May; 15(1):41. PubMed ID: 28521752
[TBL] [Abstract][Full Text] [Related]
7. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
8. Dual-targeted and pH-sensitive Doxorubicin Prodrug-Microbubble Complex with Ultrasound for Tumor Treatment.
Luo W; Wen G; Yang L; Tang J; Wang J; Wang J; Zhang S; Zhang L; Ma F; Xiao L; Wang Y; Li Y
Theranostics; 2017; 7(2):452-465. PubMed ID: 28255342
[TBL] [Abstract][Full Text] [Related]
9. DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2.
Zhang Y; Jiang S; Zhang D; Bai X; Hecht SM; Chen S
Chem Commun (Camb); 2017 Jan; 53(3):573-576. PubMed ID: 27975087
[TBL] [Abstract][Full Text] [Related]
10. PEGylated liposomal doxorubicin targeted to α5β1-expressing MDA-MB-231 breast cancer cells.
Shroff K; Kokkoli E
Langmuir; 2012 Mar; 28(10):4729-36. PubMed ID: 22268611
[TBL] [Abstract][Full Text] [Related]
11. Analysis of targeted viral protein nanoparticles delivered to HER2+ tumors.
Hwang JY; Farkas DL; Medina-Kauwe LK
J Vis Exp; 2013 Jun; (76):. PubMed ID: 23851334
[TBL] [Abstract][Full Text] [Related]
12. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
Zeng X; Morgenstern R; Nyström AM
Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
[TBL] [Abstract][Full Text] [Related]
14. Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cells.
Liu CW; Lin WJ
J Drug Target; 2013 Sep; 21(8):776-86. PubMed ID: 23829387
[TBL] [Abstract][Full Text] [Related]
15. Functionalized nanoscale β-1,3-glucan to improve Her2+ breast cancer therapy: In vitro and in vivo study.
Nasrollahi Z; Mohammadi SR; Mollarazi E; Yadegari MH; Hassan ZM; Talaei F; Dinarvand R; Akbari H; Atyabi F
J Control Release; 2015 Mar; 202():49-56. PubMed ID: 25597638
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab guided nanotheranostics: A lipid based multifunctional nanoformulation for targeted drug delivery and imaging in breast cancer therapy.
Parhi P; Sahoo SK
J Colloid Interface Sci; 2015 Aug; 451():198-211. PubMed ID: 25897856
[TBL] [Abstract][Full Text] [Related]
17. Magnetic Fluorescent Nanoformulation for Intracellular Drug Delivery to Human Breast Cancer, Primary Tumors, and Tumor Biopsies: Beyond Targeting Expectations.
El-Boubbou K; Ali R; Bahhari HM; AlSaad KO; Nehdi A; Boudjelal M; AlKushi A
Bioconjug Chem; 2016 Jun; 27(6):1471-83. PubMed ID: 27269304
[TBL] [Abstract][Full Text] [Related]
18. Impact of tumor HER2/ERBB2 expression level on HER2-targeted liposomal doxorubicin-mediated drug delivery: multiple low-affinity interactions lead to a threshold effect.
Hendriks BS; Klinz SG; Reynolds JG; Espelin CW; Gaddy DF; Wickham TJ
Mol Cancer Ther; 2013 Sep; 12(9):1816-28. PubMed ID: 23723124
[TBL] [Abstract][Full Text] [Related]
19. Actively targeting D-α-tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer.
Jiang D; Gao X; Kang T; Feng X; Yao J; Yang M; Jing Y; Zhu Q; Feng J; Chen J
Nanoscale; 2016 Feb; 8(5):3100-18. PubMed ID: 26785758
[TBL] [Abstract][Full Text] [Related]
20. Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells.
Shen Y; Zhang J; Hao W; Wang T; Liu J; Xie Y; Xu S; Liu H
Int J Nanomedicine; 2018; 13():537-553. PubMed ID: 29416334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
